Asia; docetaxel; head and neck cancer; induction chemotherapy; resectability Background: Significant ethnic differences in susceptibility to the effects of chemotherapy exist. Here, we retrospectively analyzed the safety and efficacy of induction chemotherapy (ICT) with dose-modified docetaxel, cisplatin, and 5-fluorouracil (TPF) in Asian patients with borderline resectable or unresectable head and neck squamous cell carcinoma (HNSCC Results: Between March 2011 and May 2014, 52 consecutive patients with borderline resectable or unresectable HNSCC were treated with ICT TPF 90 followed by concurrent chemoradiotherapy. Forty-four patients (84.6%) received at least three cycles of ICT TPF 90 . The most commonly observed Grade 3e4 adverse events included neutropenia (35%), anemia (25%), stomatitis (35%), diarrhea (16%), and infections (13.5%). In an intention-to-treat analysis, the complete and partial response rates after ICT TPF 90 were 13.5% and 59.6%, respectively. The complete and partial response rates following radiotherapy and salvage surgery were 42.3% and 25.0%, respectively. The estimated 3-year overall survival and progression-free survival rates were 41% [95% confidence interval (CI): 25e56%] and 23% (95% CI: 10e39%), respectively. The observed median overall survival and progression-free survival were 21.0 months (95% CI: 13.3e28.7 months) and 16.0 months (95% CI: 10.7e21.3 months), respectively. Conclusion: TPF 90 is a suitable option for Asian patients with borderline resectable or unresectable HNSCC who are scheduled for ICT.
Introduction
The combination of radiotherapy (RT) and chemotherapy (CT) may improve the clinical outcomes of patients with head and neck squamous cell carcinoma (HNSCC). In this regard, the meta-analysis of CT in head and neck cancer demonstrated that concomitant chemoradiotherapy (CCRT) confers an absolute benefit of 6.5% [hazard ratio, 0.81; 95% confidence interval (CI), 0.78e0.86; p < 0.001] at 5 years. 1 In contrast, induction CT (ICT) schedules do not generally show any positive impact on overall survival (OS), the only exception being the combination of cisplatin and 5-fluorouracil (PF). 1 Although Phase III ICT trials in HNSCC patients reported that a triple regimen comprising docetaxel, cisplatin, and 5-fluorouracil (TPF) is superior to PF in terms of clinical response and survival rates, 2e4 randomized trials do not provide strong support for the use of ICT. 5, 6 In this scenario, the potential benefits of ICT in the clinical management of HNSCC patients remain a matter of debate. These observations notwithstanding, ICT continues to be commonly used for HNSCC patients.
In the era of organ-function preservation, the long-term results of the RTOG 91e11 and GORTEC 2000e01 studies demonstrated the clinical usefulness of ICT followed by RT in patients with advanced larynx or hypopharynx squamous cell carcinomas. 7, 8 Other potential clinical advantages of ICT include the following: (1) reduction in symptoms and functional improvement before RT; (2) accelerated tumor shrinkage that can reduce the need for urgent maneuvers (e.g., tracheostomy for airway obstruction, tube feeding for swallowing problems); (3) acting as an effective bridge before definitive treatment when RT cannot be initiated immediately; (4) clearance of micrometastases; and (5) in vivo assessment of treatment response that may guide subsequent therapeutic interventions. Such potential advantages are paramount in the clinical management of patients with unresectable HNSCC, for whom ICT may confer a survival benefit. 9 In light of these findings, the Taiwanese National Health Insurance implemented (as of 2011) a reimbursement program for ICT TPF performed in patients with unresectable HNSCC.
Unfortunately, ICT TPF can be associated with serious side effects, including subsequent inability to undergo definitive therapy and deaths, in a substantial proportion of patients with advanced HNSCC (especially in those with a low socioeconomic status and poor general conditions). 10 Significant ethnic differences in susceptibility to the effects of docetaxel exist, with Asian patients having a 19-fold increased risk of docetaxel-induced severe neutropenia compared with non-Asian individuals.
11 Consequently, docetaxel dose reduction has been proposed in Asian HNSCC patients. 12, 13 Another point that merits consideration is the high prevalence of betel quid chewing in the Taiwanese population, with > 80% of HNSCC patients being betel quid chewers. Notably, the incidence of severe (! Grade 3) mucositis in Taiwanese patients treated with ICT PF is significantly higher (approx. 40%) than that observed in Western populations (8e11%), 14 possibly because of betel quid chewing-related mucosa damage. 14, 15 In this scenario, a dosage adjustment optimization that can protect against toxicity without reducing the efficacy of treatment would be of paramount importance. We therefore presented the safety and efficacy of dosemodified ICT TPF in Asian patients with borderline resectable or unresectable HNSCC.
Materials and methods

Patients
TPF was reimbursed for unresectable HNSCC by the Taiwan National Health Insurance since January 2011. Since then, patients with biopsy-proven HNSCC judged to be borderline resectable or unresectable by a multidisciplinary tumor board were enrolled if their consent to ICT TPF was obtained. All patients were staged according to the American Joint Committee on Cancer 2010 staging criteria. 16 Patients had to meet the following criteria to receive ICT TPF: (1) age 70 years; (2) Eastern Cooperative Oncology Group performance status between 0 and 2; (3) adequate bone marrow function (leukocyte count ! 4000/L; platelet count ! 100,000/L); and (4) acceptable renal (serum creatinine < 2.0 mg/dL) and liver (total bilirubin 1.5 Â the upper limit of normal; serum glutamic oxaloacetic transaminase and serum glutamic pyruvic transaminase 2.5 Â the upper limit of normal) function. Exclusion criteria were as follows: (1) 
Treatment design
ICT TPF 90 was administered every 3 weeks (defined as 1 cycle) for up to three to four cycles. However, the treatment was stopped in the presence of the following conditions: (1) progressive disease; (2) unacceptable adverse events occurring during the first or the second cycle; and (3) withdrawal from the study. Ciprofloxacin prophylaxis (500 mg orally twice a day) was performed from Day 8 to Day 14 of each cycle for their possible effect on the decrement of infection. 2, 17 Granulocyte colony-stimulating factor was permitted only in patients with febrile neutropenia or infections. Patients who experienced ! Grade 3 neutropenia in previous treatment would receive reduceddosage TPF rather than prophylactic granulocyte colonystimulating factor.
Patients who received ICT TPF at the recommended dosage were allowed to delay the next cycle until the severity of adverse events resolved to Grade 1. However, delays of 2 weeks or longer were considered as treatment discontinuations. Dose modifications in subsequent cycles were required in presence of Grade 3 toxicity (the only exceptions being the onset of alopecia, fatigue, malaise, and nail changes). We planned a 10% parallel dose deescalation of each agent at each step of dose modification. However, we did not perform docetaxel dose reductions when adverse events were obviously caused by cisplatin (e.g., nephrotoxicity) or 5-fluorouracil (e.g., mucositis).
Because TPF differs from PF in terms of docetaxel use, the TPF dose level was calculated in relation to docetaxel dosing. Patients who required a dose reduction to less than 80% of the original TPF dosage (TPF 80 ) were withdrawn from the ICT schedule. Following ICT, patients were scheduled to receive weekly cisplatin 40 mg/m 2 with concurrent RT. However, the CT regimens could be changed at the physician's discretion in patients with disease progression or poor general conditions because of ICT.
External beam RT (6 MV X-rays) was delivered through intensity-modulated techniques. Patients received 2.0 Gy/ fraction once daily, 5 fractions per week. The gross target volume (GTV) was defined according to both nasopharyngolaryngoscope and imaging findings (magnetic resonance imaging, computed tomography, and 18 Ffluorodeoxyglucose-positron emission tomography). The prophylactic clinical target volume was initially designed to include the neck lymphatics at risk and all the tissue located within 1 cm of the GTV (dose: 46e50 Gy). Subsequently, the radiation field was restricted to the GTV, the tissue located within 0.5 cm of the GTV, and the grossly involved nodal area (dose: 70e76 Gy). The maximal dose allowed for spinal cord and brain stem irradiation was 50e60 Gy. The mean dose for parotid sparing was limited to 23 Gy, whereas uninvolved constrict muscles did not receive more than 56 Gy whenever possible.
Salvage surgery for resectable residual disease was performed between 6 weeks and 12 weeks following CCRT termination. Patients who had N2 or N3 nodal disease at the initial presentation and showed complete responses to CCRT did not undergo elective neck dissection.
Tumor clinical assessments were performed every 3 weeks throughout the entire ICT treatment period. Head and neck imaging (computed tomography or magnetic resonance imaging) was scheduled: (1) at the end of ICT TPF; (2) following CCRT; and (3) in patients who showed disease progression. Post-CCRT monitoring was performed on a monthly basis during the 1 st year, every 2 months during the 2 nd year, every 3 months during the 3 rd year, and every 6 months thereafter (until the date of data censoring or death).
Statistical analysis
Time-to-event endpoints were calculated from the beginning of ICT TPF 90 to the time of death from any cause (OS) or the time to disease progression, relapse, or death from any cause (progression-free survival, PFS). All time-toevent endpoints were analyzed on an intention-to-treat basis. Time-to-event data were plotted using the KaplaneMeier method (log-rank test). Adverse events were analyzed in the safety population who received at least one ICT TPF 90 cycle. All calculations were performed using the SPSS statistical package, version 18.0 (SPSS Inc., Chicago, IL, USA). A p value < 0.05 (two tailed) was considered statistically significant.
Results
Between March 2011 and May 2014, a total of 52 consecutive patients who received ICT TPF 90 were examined.
Dose-modified induction TPF in Asian head and neck cancer
Patients were censored on May 2015 (corresponding to at least 1 year of follow up for the last patient included in the study). Table 1 shows the general features of the 52 study patients. Fifty patients (96.2%) were males, and the most common primary tumor site was the oropharynx (44.2%). Forty-six patients (88.5%) had T4 disease and 44 (84.7%) patients had N2eN3 disease. All the patients had Stage IV disease. Tumors were deemed to be borderline resectable and unresectable in 18 (34.6%) and 34 (65.4%) patients, respectively.
Forty-four patients (84.6%) received at least three cycles of ICT with modified TPF (TPFm)
Patients who received at least one cycle of TPF 90 were included in the safety analysis (Table 2) . Grade 3À4 adverse events, which occurred in at least 10% of the study patients, were as follows: neutropenia (35%), anemia (25%), stomatitis (35%), diarrhea (16%), and infections (13.5%). Five of the seven patients (13.5%) who experienced infections also had neutropenia. One patient who did not develop any obvious adverse event (as assessed in the patient's 1 st clinical visit performed after the initial TPF 90 cycle) died at home of unknown cause on the 9 th day of ICT. The TPFm cycles were administered at a median interval of 23 days (range: 20e31 days). Treatment delays of ! 7 days were identified in 17 patients (32.7%). The reasons for treatment delays included the occurrence of adverse events in eight patients (15.4%) and other reasons (mainly related to administration issues) in the remaining nine patients (17.3%). Thirteen patients (25%) had their dose reduced from TPF 90 to TPF 80 for their second ICT cycle. Dose reductions were mainly due to the occurrence of nonhematologic adverse events. Forty-two (80.8%) patients had either gained weight or maintained their body weight at the end of ICT.
The intention-to-treat overall response rate (RR) after ICT TPF 90 was 73.1%, with the complete response (CR) and partial response (PR) rates being 13.5% (7 patients) and 59.6% (31 patients), respectively.
Eight patients (15.4%) did not receive the originally scheduled RT following ICT TPF 90 for the following reasons: consent withdrawal (n Z 5), suspected lung metastasis (n Z 1), surgery (n Z 1), and death (n Z 1). Forty-four patients (84.6%) received post-ICT CCRT. The median time interval between the finish of the last ICT TPF to the start of RT was 20.5 days (range, 0e56 days). The CT schemes and therapeutic compliance are summarized in Table 3 . The median duration of RT was 52 days (range: 38e75 days) with a median dosage of 72 Gy (range: 56e80.2 Gy). Only one patient who died of pneumonia within 30 days of the end of CCRT received an RT dose of < 60 Gy.
The intention-to-treat overall RR after CCRT was 65.3%. The CR and PR rates were 28.8% (15 patients) and 36.5% (19 patients), respectively. Seven patients (13.5%) received salvage surgery for the presence of residual disease (2 patients at lymph nodes only and 5 patients at both the primary tumor and the nodes). After salvage surgery, the intention-to-treat overall RR was 67.3%, with CR and PR rates being 42.3% (22 patients) and 25.0% (13 patients), respectively.
In the last survival analysis performed in May 2015, the median follow-up time of the 21 surviving patients was 34 months. The median OS and PFS durations were 21 months (95% CI: 14e28 months) and 16 months (95% CI: 11e21 months), respectively (Figures 1 and 2 ). The estimated 3-year OS and PFS rates were 41% (95% CI: 25e56%) and 23% (95% CI: 10e39%), respectively. Treatment failures occurred in 34 patients (65%). Initial failures had the following distribution: locoregional failure (n Z 20; 38%); locoregional and distant failure (n Z 4; 8%); distant failure only (n Z 6; 11%); second primary tumor failure (n Z 1; 2%); and early withdrawal according to the study protocol (n Z 3; 6%).
Discussion
A proper selection of candidates is paramount to optimize the success of ICT. In accordance with our treatment guideline, ICT TPF was specifically focused on patients with borderline resectable or unresectable HNSCC because they can potentially benefit from this approach. 18 However, the classification of a tumor as either borderline resectable or unresectable is not univocal and may be physician dependent. Herein, our multidisciplinary tumor board considered a tumor as borderline resectable or unresectable when the following criteria were met: (1) presence of very advanced local disease according to the American Joint Committee on Cancer 2010 staging criteria (pharyngeal tumors) 16 ; (2) tumor invasion occurring above the mandibular notch in patients with oral cancer 19 ; (3) marked central compartment involvement; and (4) presence of N3 disease. Patients who met such stringent criteria are deemed to have a poor prognosis.
Another critical issue is the proper selection of the TPF regimen. Two different ICT TPF dosages have been reported in the literature. 2, 17 The combined regimen of docetaxel Figure 1 KaplaneMeier plots of overall survival (patients at risk and 95% confidence intervals are depicted). Figure 2 KaplaneMeier plots of progression-free survival (patients at risk and 95% confidence intervals are depicted). 17 As 5-fluorouracil at a dose of 1000 mg/m 2 /d has been shown to cause a high incidence of stomatitis at 96e120 hours of infusion in our patients, 14, 15 we selected the TAX 323 trial dosage as the reference regimen (TPF 100 ). TPF 90 was then selected as the optimal dosage for ICT TPF in our clinical scenario. The observation that 25% (< 33%) of the treated patients required a dose reduction from TPF 90 to TPF 80 during the second ICT cycle supported the clinical feasibility of TPF 90 as an ICT regimen.
Dose-modified induction TPF in
The exact number of ICT cycles to be conducted before locoregional therapy has not been clearly established. In general, three to four cycles of ICT are required to ensure optimal clinical results, 20 but the total number may vary according to the RRs and the incidence of adverse events. Herein, 44 patients (84.6%) received ! 3 ICT TPFm cycles. The methodology used in the current study (including the patient population and the TPF regimen) is similar to that of the TAX 323 trial. 2 The major Grade 3e4 adverse events observed in our study and in the TAX 323 trial were as follows: neutropenia 35% versus 77%; anemia 25% versus 9%; stomatitis 35% versus 5%; diarrhea 16% versus 3%; and infections 13.5% versus 6.9%. Despite a lower incidence of neutropenia, severe stomatitis and diarrhea occurred at a relatively high frequency in our patients. As betel quid chewing-related changes in the oral mucosa cannot easily explain these observations, we believe that they may be dependent on ethnic or genetic factors that warrant further scrutiny.
In this study, TPF 90 cycles were administered at a median interval of 23 days from each other (range: 20e31 days), and the dose intensity was 82% of the original TPF regimen. The dose intensity of cisplatin can have an impact on the clinical outcomes of HNSCC patients undergoing CCRT. 21, 22 However, the question as to whether the dose intensity of ICT TPF can affect the therapeutic results remains open. Despite using an ICT TPF regimen with a lower dose intensity, the CR and PR rates observed in our intention-to-treat population (13.5% and 59.6%, respectively) were similar to those reported in the TAX 323 trial (8.5% and 59.3%, respectively).
In general, disease control is largely dependent on an effective post-ICT locoregional therapy (mainly RT or CCRT for unresectable HNSCC). However, a substantial proportion of patients with unresectable disease did not receive RT in the current study (mainly because of disease progression or the onset of ICT TPF-related adverse events). It is nonetheless worth noting that only 15.4% of our patients were not treated with RT, a substantially lower proportion than those reported (27e31%) in previous ICT TPF trials conducted in patients with unresectable HNSCC. 2, 23 The CT regimen used for post-ICT CCRT is another critical determinant of outcomes in patients with advanced HNSCC. In the current study, weekly cisplatin 40 mg/m 2 was used in combination with RT (a commonly used alternative to 3-weekly cisplatin 100 mg/m 2 in Asian countries). 24 Using weekly cisplatin 40 mg/m 2 , the major Grade 3e4 adverse events of CCRT observed after ICT TPF compared with our postsurgery adjuvant setting were as follows: neutropenia 29% versus 12%, anemia 30% versus 9%, stomatitis 78% versus 67%, and dermatitis 15% versus 6%. 25 These data suggest that ICT TPF may increase the severity of adverse events of the following CCRT. Although previous studies utilized different approaches (i.e., RT alone, CCRT with various CT regimens, and bioradiotherapy with cetuximab), 2, 5, 6, 17, 26, 27 the optimal strategy for minimizing treatment-related morbidity has not been yet identified.
Herein, the estimated 3-year OS and PFS rates were 41% and 23%, respectively (Figures 1 and 2) , with the median OS and PFS durations being 21.0 months and 16.0 months, respectively. The ICT TPF arm included in the TAX 323 trial showed an OS rate of 37% and a median OS of 18.8 months. 2 Moreover, the Spanish Head and Neck Cancer Cooperative Group (TTCC) trial reported median OS and PFS durations of 27.0 months and 14.6 months, respectively. 23 The different number and characteristics of the study patients may, at least in part, explain the observed differences in survival rates. In the current study, 13.5% of patients who underwent ICT TPF were surgically salvaged. The use of salvage surgery in the TAX 323 and TTCC trials was 15.3% and 27.1%, respectively, suggesting important differences in the study participants. A previous Taiwanese retrospective study conducted in patients with unresectable tumors or candidates for organ preservation who were treated with ICT at a dose similar to TPF 80 reported a median PFS of 435 days. 12 Twenty-three (44%) of our patients had oropharyngeal cancer. Twelve patients were examined for p16 expression by immunohistochemistry, and three (25%) of them had strong diffuse nuclear and cytoplasmic immunohistochemistry staining of p16 in more than 70% of tumor cells. Such patients were considered to have human papillomavirus (HPV)-related HNSCC. 28 No positive p16 staining was observed in the remaining nine patients. The three HPVpositive patients had T4 disease, ultimately being at high risk according to the refined American Joint Committee on Cancer criteria for HPV-related oropharyngeal squamous cell carcinoma. 29 All of them died of disease with an OS of 4 months, 8 months, and 21 months. In Taiwan, the incidence of HPV-related site HNSCC (1.3/100,000 in 1995 to 3.3/100,000 in 2009, annual percentage change 56.9, p < 0.0001) has increased more rapidly than that of HPVunrelated site HNSCC (10.4/100,000 in 1995 to 21.7/ 100,000 in 2009, annual percentage change 55.0, p < 0.0001). 30 However, the HPV-positive rates in Taiwan (13e17%) remain significantly lower than those reported in industrialized countries. 31, 32 In this context, optimization of intensive therapeutic approaches with an acceptable burden of adverse events is paramount, especially for HPVunrelated HNSCC patients.
In conclusion, our experience indicates that TPF 90 is a suitable option for Asian patients with borderline resectable or unresectable HNSCC who are scheduled for ICT TPF. Despite the reduced dosage, such an approach allowed us to achieve survival figures similar to those reported for the original dose regimen. However, we acknowledge the shortcomings of our report. The dose reduction to 90% was not through a Phase I study and was chosen in accordance with the adverse events in a small number of patients. Can a dose reduction of more than 10% further reduce the adverse effects and have a comparative efficacy? Future studies aiming at both identifying the ideal candidates for ICT TPF and optimizing the balance between its efficacy and toxicity are needed.
